Milind Javle

Milind Javle at MD Anderson is a cholangiocarcinoma specialist who has conducted comprehensive genomic profiling studies defining the molecular landscape of intrahepatic versus extrahepatic cholangiocarcinoma. His work has characterized the prevalence of FGFR2 fusions, IDH1 mutations, KRAS, HER2, and other actionable alterations across BTC subtypes. He has been involved in early-phase trials of multiple FGFR inhibitors and has contributed to understanding the therapeutic implications of the distinct molecular profiles of iCCA versus eCCA. His comprehensive molecular profiling approach to BTC has influenced treatment guidelines.